Close-up of an array of test tubes in a laboratory
Our Work

Latham & Watkins Advises Innocoll Biotherapeutics in US$125 Million Term Loan with Leading Biotech Investor Oaktree Capital

February 1, 2022
Firm represents the international specialty pharmaceutical company in a growth financing transaction.

Innocoll Biotherapeutics plc, a specialty pharmaceutical company and portfolio business of Gurnet Point Capital, has announced the successful closing of a new US$125 million term loan provided by funds managed by Oaktree Capital Management, L.P.

Latham & Watkins LLP represents Innocoll Biotherapeutics with a transactional team led by California finance partners Haim Zaltzman and Elizabeth Oh, with associates Hyunji Lee and Dong Whi (Tony) Noh. Advice has also been provided on corporate matters by California partner Ben Potter and Boston associate Erik Thompson; on intellectual property matters by California partners Judith Hasko and Jekkie Kim; on ERISA matters by California partner Julie Crisp; on regulatory matters by California counsel Betty Pang and Washington, D.C. associate Chad Jennings; on tax matters by California partner Katharine Moir and associate Alexander Farris; and on German legal matters by Frankfurt partner Torsten Volkholz and associate Anna-Maria Kuckerz.

    Related Capabilities